Popular on TelAve
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
- The ITeam Ranked on Channel Partners 2025 MSP 501—Tech Industry's Most Prestigious List of Managed Service Providers Worldwide
- Keepy Uppy™ by Ollyball Wins Prestigious 2025 Influencer Award from Clamour & The Toy Association; Announces Fall 2025 Launch at Target Stores
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
- Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a "Clean Start"
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence
- TCAA Welcomes Adolfo Gomez Sanchez to Its Family of Talented Speakers
- Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
- Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
- IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
Similar on TelAve
- Pixel Studio Productions Launches Same-Day Headshots in Houston
- SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
- Nonprofit innovator named Mensa Executive Director
- Yasmine Roulleau named Managing Director in Vancouver, Canada
- Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
- Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
Breaking research could help to advance care for overdose patients who've taken xylazine
TelAve News/10847151
WASHINGTON, Nov. 20, 2024 ~ A recent study published in the journal Clinical Chemistry by researchers at the Washington University School of Medicine in St. Louis has shed light on the body's ability to clear xylazine, a popular emerging drug of abuse in the United States. The study, conducted by a team led by Bridgit Crews, PhD, found that it takes much longer for the human body to process xylazine than previously thought.
Xylazine is traditionally used as a tranquilizer in veterinary practice, but its use as a recreational drug has been on the rise. According to a report from the Centers for Disease Control and Prevention, between 2019 and 2022, there has been a 276% increase in detection of xylazine in fentanyl-associated overdose deaths. This is concerning because unlike opioids, Narcan does not work to revive individuals who have taken xylazine. Furthermore, there is limited research on how xylazine affects humans, making it difficult for healthcare providers to effectively treat patients who have used it.
In an effort to address this gap in knowledge about xylazine, Dr. Crews and her team set out to determine how long the drug remains in the body. They initially identified 493 patients who had used xylazine and also tested positive for fentanyl. After narrowing down their sample size based on specific criteria, they were left with 28 patients whose blood samples could be used to assess xylazine's half-life.
More on TelAve News
The half-life of a drug refers to the amount of time it takes for its concentration in the blood to decrease by half. By analyzing these blood samples over time, the researchers found that on average, xylazine has a half-life of 12 hours in humans. This is longer than what has been observed in animal studies and a previous case study involving one human subject which showed a half-life of nearly 5 hours.
This finding suggests that xylazine can remain in the human body for up to 2 days after an individual's last exposure, depending on the amount ingested. Additionally, the team identified metabolites of xylazine that could aid in its detection and improve clinical testing for the drug.
Dr. Crews emphasized the importance of this study in understanding the effects of xylazine on humans, especially in those who may chronically use fentanyl mixed with xylazine. She believes that a better understanding of typical xylazine concentrations and its duration in the body can help improve interpretation of clinical studies, establish appropriate cutoffs for surveillance, and inform treatment and monitoring strategies for patients at risk.
This novel study provides valuable insights into how the human body processes xylazine and highlights the need for further research on this emerging drug of abuse. The full study can be accessed at https://doi.org/10.1093/clinchem/hvae163.
Xylazine is traditionally used as a tranquilizer in veterinary practice, but its use as a recreational drug has been on the rise. According to a report from the Centers for Disease Control and Prevention, between 2019 and 2022, there has been a 276% increase in detection of xylazine in fentanyl-associated overdose deaths. This is concerning because unlike opioids, Narcan does not work to revive individuals who have taken xylazine. Furthermore, there is limited research on how xylazine affects humans, making it difficult for healthcare providers to effectively treat patients who have used it.
In an effort to address this gap in knowledge about xylazine, Dr. Crews and her team set out to determine how long the drug remains in the body. They initially identified 493 patients who had used xylazine and also tested positive for fentanyl. After narrowing down their sample size based on specific criteria, they were left with 28 patients whose blood samples could be used to assess xylazine's half-life.
More on TelAve News
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
The half-life of a drug refers to the amount of time it takes for its concentration in the blood to decrease by half. By analyzing these blood samples over time, the researchers found that on average, xylazine has a half-life of 12 hours in humans. This is longer than what has been observed in animal studies and a previous case study involving one human subject which showed a half-life of nearly 5 hours.
This finding suggests that xylazine can remain in the human body for up to 2 days after an individual's last exposure, depending on the amount ingested. Additionally, the team identified metabolites of xylazine that could aid in its detection and improve clinical testing for the drug.
Dr. Crews emphasized the importance of this study in understanding the effects of xylazine on humans, especially in those who may chronically use fentanyl mixed with xylazine. She believes that a better understanding of typical xylazine concentrations and its duration in the body can help improve interpretation of clinical studies, establish appropriate cutoffs for surveillance, and inform treatment and monitoring strategies for patients at risk.
This novel study provides valuable insights into how the human body processes xylazine and highlights the need for further research on this emerging drug of abuse. The full study can be accessed at https://doi.org/10.1093/clinchem/hvae163.
Filed Under: Business
0 Comments
Latest on TelAve News
- NWIDA Welcomes Matt Zieminski to Board of Directors as Legislative Strategy Lead
- $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
- $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
- Disposable Vape Ban Spurs Hayati Innovation
- Prolific Hollywood "Unknown Actor" Leads 11 Day SoCal, Hands-On, Performer Employment Securing Residency that Shows Others How to Get More Work
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
- Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
- Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
- Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
- Opteamix Launches StackRewrite.AI to Transform Enterprise Legacy Modernization
- "The Pornified Generation": Dr. Chris Samuels Exposes the Toxic Alliance Between Bro Culture and Pornography That's Rewiring a Generation
- Bill Perfect Achieves SOC 1 Type II Compliance With No Exceptions
- The Modern Insurance Store Expands Medicare Help Services for Seniors in Cincinnati
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates